A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

The kidneys have a crucial role to play in the overall health of an individual—they remove waste, maintain fluid and ...

Mountain adventures promise stunning views and unforgettable memories, but ascending to high elevations triggers profound ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

Four climbers went up and down Everest in under a week with the help of xenon gas—a record-breaking ascent that has ignited ...

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively.

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

In the case presented here, the erythropoietin level was determined by the IMMULITE ® 1000 (Cirrus Diagnostics Inc., Los Angeles, CA, USA), a solid-phase chemiluminescent immunometric assay.

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

His red blood cell count showed erythrocytosis (7.0 × 10 12 /l), a raised hemoglobin level of 220 g/l and an increased erythropoietin level of 27.4 U/l (normal: 1.5-15.2 U/l), but he had normal ...

A twice-yearly injection could revolutionize how high blood pressure is treated, offering a major breakthrough for millions ...